Longwood Fund-founded oncology startup to double size with $152M
Longwood Fund-founded oncology startup to double size with $152M Read More »
March 30, 2021
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
— New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I/O) programs to next value inflection point —— In addition to recently announced in-licensed ADC candidates and ADC toolkit from Pfizer, funding to support in-licensed ADC candidate from LegoChem Biosciences — CAMBRIDGE, Mass., March, 30, 2021 – Pyxis Oncology (“Pyxis” or the
